This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Menlo Therapeutics, Inc.
Drug Names(s): MK-0594, MK0594, MK 0594, VPD-737, VPD 737, VPD737
Description: Serlopitant is a potent oral NK1 receptor antagonist.
Menlo and Merck
In 2012, Menlo Therapeutics (formerly Tigercat) exclusively licensed serlopitant, a potent oral NK1 receptor antagonist, from Merck.
Japan Tobacco, Torii, and Menlo
In August 2016, Japan Tobacco and Torii Pharmaceutical announced that the companies have signed an exclusive license agreement with Menlo Therapeutics for the development and commercialization of serlopitant in Japan. Under the terms of the agreement, JT and Torii will jointly develop serlopitant in Japan and Torii will be commercializing it, once the development and necessary approval procedures have been completed. The companies will pay to Menlo Therapeutics upfront licensing fees and payments upon the achievement of certain milestones, and royalties based on future sales in Japan.
Partners: Velocity Pharmaceutical Development, LLC Japan Tobacco Inc. Torii Pharmaceutical Co., Ltd.
Additional information available to subscribers only: